Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31563959

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2020 Jan 1
First author
Sledge GW Jr

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2019 Dec;16(12):722. doi: 10.1038/s41571-019-0288-z.
    note
    Source null
    related pmid
    31605029
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2020 Jul 1;6(7):1122. doi: 10.1001/jamaoncol.2020.1516.
    note
    Source null
    related pmid
    32463423
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2020 Jul 1;6(7):1121-1122. doi: 10.1001/jamaoncol.2020.1513.
    note
    Source null
    related pmid
    32463424
    relationship
    Comment in
  4. citation
    JAMA Oncol. 2020 Jul 1;6(7):1122-1123. doi: 10.1001/jamaoncol.2020.1518.
    note
    Source null
    related pmid
    32463426
    relationship
    Comment in

Authors and identifiers

  1. name
    Sledge GW Jr
    type
    Author
  2. name
    Toi M
    type
    Author
  3. name
    Neven P
    type
    Author
  4. name
    Sohn J
    type
    Author
  5. name
    Inoue K
    type
    Author
  6. name
    Pivot X
    type
    Author
  7. name
    Burdaeva O
    type
    Author
  8. name
    Okera M
    type
    Author
  9. name
    Masuda N
    type
    Author
  10. name
    Kaufman PA
    type
    Author
  11. name
    Koh H
    type
    Author
  12. name
    Grischke EM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Sledge GW Jr
    type
    Author
  2. name
    Toi M
    type
    Author
  3. name
    Neven P
    type
    Author
  4. name
    Sohn J
    type
    Author
  5. name
    Inoue K
    type
    Author
  6. name
    Pivot X
    type
    Author
  7. name
    Burdaeva O
    type
    Author
  8. name
    Okera M
    type
    Author
  9. name
    Masuda N
    type
    Author
  10. name
    Kaufman PA
    type
    Author
  11. name
    Koh H
    type
    Author
  12. name
    Grischke EM
    type
    Author
bibliography ids
  1. nci-bib-2909bfc017f1b8e76f9bbf98
book metadata
content sha256
d2a62c6283fc1f7a86a82f20a47eeb46bb44bf9dc44e969d73e409e1a747d7f9
document type
citation
dois
  1. 10.1001/jamaoncol.2019.4782
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:31563959
immutable id
pubmed:31563959@d2a62c6283fc1f7a86a82f20a47eeb46bb44bf9dc44e969d73e409e1a747d7f9
journal
abbreviation
JAMA Oncol
issn electronic
2374-2445
issn print
2374-2437
issue
1
name
JAMA oncology
nlm unique id
101652861
pages
116-124
volume
6
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2019 Dec;16(12):722. doi: 10.1038/s41571-019-0288-z.
    note
    Source null
    related pmid
    31605029
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2020 Jul 1;6(7):1122. doi: 10.1001/jamaoncol.2020.1516.
    note
    Source null
    related pmid
    32463423
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2020 Jul 1;6(7):1121-1122. doi: 10.1001/jamaoncol.2020.1513.
    note
    Source null
    related pmid
    32463424
    relationship
    Comment in
  4. citation
    JAMA Oncol. 2020 Jul 1;6(7):1122-1123. doi: 10.1001/jamaoncol.2020.1518.
    note
    Source null
    related pmid
    32463426
    relationship
    Comment in
outcomes validated
false
pmid
31563959
provenance
batch id
23ffe1e2a9e160b6dca0
provider
NCBI PubMed ESummary
record sha256
0e7ee19882cea193ca076e2bf3b25e573366fd93099bae2c3094604caf5464ef
response sha256
d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
retrieved at
2026-09-09T23:47:44.690737+00:00
publication date
display
2020 Jan 1
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31563959/
title
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Preserved source evidence · Not medical advice